Doctors Without Borders (MSF) isMSF has identified price as a barrier to the use of insulin pens in LMICs. The nonprofit published a paper on insulin pen prices in March, in which it said the ...

At the time, the NYT noted that no other company had bid on the contract, which covered supply of 14 million pens for three years at roughly $2 per device. Novo had been supplying insulin pens to ...

South Africa's competition watchdog is investigating drugmakers Novo Nordisk and Sanofi over possible anti-competitive practices in the human insulin pen market, the authority said on Tuesday.

MSF estimates insulin pens can be produced for $0.94 while being profitable; current U.S. price is $90.69. Diabetes affects 537 million globally, with African cases expected to rise by 134% by ...

Novo Nordisk A/S and Sanofi are under investigation in South Africa for potential anti-competitive practices in the human insulin pen market. Novo Nordisk decided not to bid for the 2024 tender ...

Novo Nordisk is also discontinuing two insulin detemir solutions — Levemir Flexpen subcutaneous injection, 100 units per milliliter pen; and Levemir subcutaneous injection, 100 units per ...

For now, making insulin locally may help ease the crunch. Aspen Pharmacare Holdings Ltd., based in Durban, is pushing into diabetes care, with a contract to make Novo’s human insulin.

The "Insulin Pens Market - Global Outlook & Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering. The insulin pens market is expected to grow at a CAGR of 6.26% during ...

Novo Nordisk has agreed to cap the price of insulin at $35 per month for uninsured New Yorkers, according to Attorney General Letitia James.

Novo Nordisk launches its first GLP-1 product, liraglutide, branded as Victoza in 2009 in Europe and in 2010 in the U.S. In 2013, Novo Nordisk's semaglutide starts global phase 3 trials.

Novo launched the NovoPen - the first insulin pen device in 1985. 2000–2017 Lars Rebien Sorensen becomes CEO after serving as the head of Novo's healthcare business.